Burney Co. Has $225,000 Position in Incyte Co. (NASDAQ:INCY)

Burney Co. grew its holdings in Incyte Co. (NASDAQ:INCY) by 7.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,262 shares of the biopharmaceutical company’s stock after acquiring an additional 223 shares during the period. Burney Co.’s holdings in Incyte were worth $225,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Haverford Trust Co boosted its stake in Incyte by 1.8% in the third quarter. Haverford Trust Co now owns 7,796 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 135 shares in the last quarter. V Square Quantitative Management LLC lifted its stake in shares of Incyte by 4.1% during the third quarter. V Square Quantitative Management LLC now owns 3,963 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 155 shares during the period. Tectonic Advisors LLC lifted its stake in shares of Incyte by 1.6% during the third quarter. Tectonic Advisors LLC now owns 12,390 shares of the biopharmaceutical company’s stock valued at $819,000 after acquiring an additional 190 shares during the period. 180 Wealth Advisors LLC lifted its stake in shares of Incyte by 3.9% during the fourth quarter. 180 Wealth Advisors LLC now owns 5,231 shares of the biopharmaceutical company’s stock valued at $361,000 after acquiring an additional 195 shares during the period. Finally, MML Investors Services LLC lifted its stake in shares of Incyte by 4.4% during the third quarter. MML Investors Services LLC now owns 6,063 shares of the biopharmaceutical company’s stock valued at $401,000 after acquiring an additional 256 shares during the period. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Stock Down 0.7 %

Shares of Incyte stock opened at $71.93 on Friday. Incyte Co. has a 1 year low of $50.35 and a 1 year high of $83.95. The business has a 50-day moving average of $72.36 and a two-hundred day moving average of $67.98. The company has a market capitalization of $13.86 billion, a P/E ratio of 513.82, a price-to-earnings-growth ratio of 0.51 and a beta of 0.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.87 and a quick ratio of 1.82.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by ($0.12). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter last year, the company earned $0.91 earnings per share. The firm’s revenue was up 23.8% compared to the same quarter last year. As a group, equities analysts predict that Incyte Co. will post 0.4 EPS for the current year.

Analyst Ratings Changes

INCY has been the topic of several research reports. JMP Securities reaffirmed a “market perform” rating on shares of Incyte in a research note on Tuesday, January 14th. Oppenheimer upped their price target on Incyte from $81.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Citigroup upped their price target on Incyte from $92.00 to $97.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Wolfe Research began coverage on Incyte in a research note on Tuesday, October 1st. They issued an “outperform” rating and a $84.00 target price on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Incyte has a consensus rating of “Hold” and a consensus target price of $76.29.

Insider Buying and Selling

In related news, EVP Vijay K. Iyengar sold 6,043 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $75.38, for a total transaction of $455,521.34. Following the completion of the transaction, the executive vice president now directly owns 30,658 shares in the company, valued at approximately $2,311,000.04. This trade represents a 16.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Thomas Tray sold 650 shares of the stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $70.64, for a total value of $45,916.00. Following the transaction, the insider now owns 23,962 shares of the company’s stock, valued at approximately $1,692,675.68. The trade was a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,023 shares of company stock worth $839,711. 17.60% of the stock is owned by corporate insiders.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.